Dyslipidemia

Type: Keyphrase
Name: Dyslipidemia
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Dr. Peter O. Kwiterovich Jr., expert on lipid disorders

Dr. Peter O. Kwiterovich Jr., an internationally known expert on lipid disorders who was the founder and director of the Johns Hopkins Lipid Clinic and was an early advocate for routine cholesterol screening in children, died Friday of prostate cancer ... [Published Baltimore Sun - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension

Press Release   View printer-friendly version <<  Back First liquid formulation clozapine for treatment-resistant schizophreniaDUBLIN , Feb. 11, 2014 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability ... [Published Longitude Capital - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Decision Resources Group Triples Coverage On U.S. Longitudinal Patient Claims Data Analytics

BURLINGTON, Mass. , Aug. 18, 2014 /PRNewswire/ -- Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series , which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's ... [Published CEOWorld Magazine - Aug 18 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Combination of Alcohol and Fructose Exacerbates Metabolic Imbalance in Terms of Hepatic Damage, Dyslipidemia, and Insulin Resistance in Rats

by Salamah Mohammad Alwahsh, Min Xu, Frank Christian Schultze, Jörg Wilting, Sabine Mihm, Dirk Raddatz, Giuliano RamadoriAlthough both alcohol and fructose are particularly steatogenic, their long-term effect in the development of a metabolic syndrome ... [Published Plosone.org - Aug 07 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

New Findings from Department of Nephrology Update Understanding of Antineoplastics (More Potent Lipid-Lowering Effect by Rosuvastatin Compared With...

New Findings from Department of Nephrology Update Understanding of Antineoplastics (More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients)By a News Reporter-Staff News Editor at Biotech ... [Published HispanicBusiness.com - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 5 reports

Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia

Other key findings from the DecisionBase report entitled : Comments from Research Associate Stefanie Hoffart, M. Sc.: Ms. Hoffart has written a blog on the subject, which can be found here.About Decision Resources GroupDecision Resources Group offers ... [Published Wall Street Select - Jul 21 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Reports from C.N. Ferreira et al Highlight Recent Findings in Vascular Diseases (Hyper-coagulable profile with elevated pro-thrombotic biomarkers and...

Reports from C.N. Ferreira et al Highlight Recent Findings in Vascular Diseases (Hyper-coagulable profile with elevated pro-thrombotic biomarkers and increased cerebro- and cardio-vascular disease risk exist among healthy dyslipidemic women)By a News ... [Published 4 Traders - Jul 16 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Research and Markets: Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dk238k/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market" report to their offering. ... [Published Business Wire Health News - Jun 27 2014]
Entities: Lipid, Pipeline, Market
First reported Jun 03 2014 - Updated Jun 03 2014 - 1 reports

Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014... ... [Published PR Newswire: Health - Jun 03 2014]
First reported May 28 2014 - Updated May 28 2014 - 1 reports

Research and Markets: Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s8k8lc/mixed) has announced the addition of the "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, ... [Published Business Wire Professional Services News - May 28 2014]
First reported May 01 2014 - Updated May 01 2014 - 3 reports

The National Lipid Association Releases Draft Recommendations for Patient-Centered Treatment of Dyslipidemia

ORLANDO, Fla.--(EON: Enhanced Online News)--The National Lipid Association recently convened an Expert Panel to draft a document that would serve as guidance to clinicians for treating patients with dyslipidemia. ... [Published EON Science - May 01 2014]
Entities: Lipid, Dyslipidemia
First reported May 01 2014 - Updated May 01 2014 - 1 reports

Data Showed After 52 Weeks, LIVALO® (pitavastatin) 4 mg Maintained Similar Safety and Significantly Greater LDL-C Reduction Compared with Pravastatin 40 mg in HIV-infected Adults with Dyslipidemia

ORLANDO, Fla., May 1, 2014 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating ... [Published PR Newswire: General Business - May 01 2014]

Quotes

"We have lost a true giant in the field of cardiovascular disease . He was one of the quiet pioneers at Hopkins" said Dr. George J Dover, pediatrician-in-chief at Johns Hopkins Hospital and director of the Johns Hopkins Children's Center
...treatments while failing to maintain adequate symptom control," said Gustavo Alva , MD, DFAPA, Medical Director at ATP Clinical Research .   "When patients reach this stage, the next move matters – now with oral suspension Versacloz, we have another option to help patients."
"Each module in this series helps marketers understand trends in drug utilization for a specific disease area. Whether they are tracking a new product launch or analyzing the impact of a generic entry, this tool clearly shows how prescribing patterns change in reaction to these market dynamics. Based on client demand, we've decided to expand our 2014 research suite to include 19 new report titles, encompassing an even greater breadth of disease-level analysis."
According to the news editors, the research concluded: "The combination of everolimus/rosuvastatin seems to be as safe as the everolimus/fluvastatin combination."

More Content

All (31) | News (16) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (4) | Press Releases (0)
sort by: Date | Relevance
Dr. Peter O. Kwiterovich Jr., expert on lipid d... [Published Baltimore Sun - Aug 20 2014]
Jazz Pharmaceuticals Announces U.S. Commercial ... [Published Longitude Capital - Aug 19 2014]
Decision Resources Group Triples Coverage On U.... [Published CEOWorld Magazine - Aug 18 2014]
News from the European Atherosclerosis Society ... [Published British Journal of Cardiology - Aug 13 2014]
Practice Guidelines for the Management of LDL-R... [Published Theheart.org - Aug 11 2014]
Combination of Alcohol and Fructose Exacerbates... [Published Plosone.org - Aug 07 2014]
KDIGO Clinical Practice Guideline for Lipid Man... [Published Theheart.org - Jul 28 2014]
New Findings from Department of Nephrology Upda... [Published HispanicBusiness.com - Jul 24 2014]
Amarin: Will The Lamb Of Ireland Bleat Or The L... [Published Seeking Alpha - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published Wall Street Select - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published BioSpace - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published Nasdaq - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published RCL Advisors - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
Reports from C.N. Ferreira et al Highlight Rece... [Published 4 Traders - Jul 16 2014]
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
Viking Signs Broad Licensing Deal With Ligand P... [Published Marketwire - Breaking News Releases - May 22 2014]
Research and Markets: Dyslipidemia - Pipeline R... [Published Business Wire Health News - May 07 2014]
The National Lipid Association Releases Draft R... [Published EON Science - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Science: Science News - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Health News - May 01 2014]
Data Showed After 52 Weeks, LIVALO® (pitavastat... [Published PR Newswire: General Business - May 01 2014]
Methods of treating mixed dyslipidemia [Published PharmCast - Apr 08 2014]
Primary Care Physicians Updated on Latest JNC 8... [Published PRWeb - Mar 18 2014]
Research and Markets: Mixed Dyslipidemia - Pipe... [Published Business Wire Health News - Feb 13 2014]
Fact Sheet for Karo Bio AB [Published Silobreaker - Mar 15 2010]
Fact Sheet for Karo Bio AB [Published Able2Act - Jul 16 2008]
Fact Sheet for Pfizer (India) Ltd. [Published Able2Act - May 06 2008]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages ...
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dk238k/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market" report to their offering. ...
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014... ...
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s8k8lc/mixed) has announced the addition of the "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, ...
Viking Signs Broad Licensing Deal With Ligand P... [Published Marketwire - Breaking News Releases - May 22 2014]
Ligand to Invest $2.5 Million to Support Development of Novel Treatments for Diabetes, Cancer Cachexia, Dyslipidemia and Anemia ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.